The second evaluates the efficacy of anti-ST2 antibody vs. placebo on the frequency of moderate-to-severe exacerbations of COPD (ClinicalTrials.gov: NCT03615040). The gene discussed is IL1RL1; the disease is chronic obstructive pulmonary disease.